뒤로
TC Biopharm (Holdings) PLC (TCBPY) 수입
TCBPY 주가 차트
TCBPY 수입
TC Biopharm (Holdings) PLC
$0.01
-56.09%
$-0.02
종가: Mar 23, 16:00:00 GMT-4
$0.01
0%
$0
프리마켓: Mar 24, 08:11:50 GMT-4
아직 데이터 없음Earnings FAQ
TCBPY의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
TC Biopharm (Holdings) PLC TCBPY의 지난 분기 매출 실적은 어땠나요?
TC Biopharm (Holdings) PLC의 매출 추정치는 얼마인가요?
TC Biopharm (Holdings) PLC의 수익 품질 점수는 얼마인가요?
TC Biopharm (Holdings) PLC는 언제 수익을 보고하나요?
TC Biopharm (Holdings) PLC의 예상 수익은 얼마인가요?
TC Biopharm (Holdings) PLC은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$0.041
시가
$0.041
일일 범위
$0.018 - $0.041
52주 범위
$0.017 - $0.69
거래량
31.2K
평균 거래량
13.7K
배당수익률
--
EPS(TTM)
-7.34
시가총액
$184.6K
TCBPY란 무엇인가요?
TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel immunotherapy products based on its proprietary allogeneic gamma delta T cell platform. The company employs 39 full-time employees The company went IPO on 2022-02-23. The firm is conducting two investigator-initiated clinical trials for its unmodified GD-T cell product line - phase IIb/III pivotal trial in treatment of AML using its allogeneic CryoTC technology to provide frozen product to clinics worldwide. Its lead product candidate, OmnImmune is an unmodified allogeneic GD-T cell product, being initially used for the treatment of AML. Its pre-clinical stage program is focused on developing CAR-modified allogeneic GD-T cell products targeting solid and hematological indications. The company has an Israeli patent and Japanese patent applications covering the method of preparing and using GD-T cells in the allogeneic treatment of subjects suffering from viral, fungal and protozoal infections or cancer.